0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the Centers for Disease Control and Prevention |

Infection Control Requirements for Dialysis Facilities and Clarification Regarding Guidance on Parenteral Medication Vials FREE

JAMA. 2008;300(17):1993. doi:10.1001/jama.300.17.1993.
Text Size: A A A
Published online

MMWR. 2008;57:875-876

In April 2008, the Centers for Medicare and Medicaid Services (CMS) published in the Federal Register its final rule on Conditions for Coverage for End-Stage Renal Disease (ESRD) Facilities.1 The rule establishes new conditions dialysis facilities must meet to be certified under the Medicare program and is intended to update CMS standards for delivery of quality care to dialysis patients. CDC's 2001 Recommendations for Preventing Transmission of Infections among Chronic Hemodialysis Patients2 have been incorporated by reference into the new CMS conditions for coverage. Thus, effective October 14, 2008, all ESRD facilities are expected to follow the CDC recommendations as a condition for receiving Medicare payment for outpatient dialysis services.

In recent years, outbreak investigations in dialysis and other health-care settings have demonstrated that mishandling of parenteral medication vials can contribute to the risk for hepatitis C virus (HCV) infection and bacterial and other infections.37 In 2002, a CDC communication to CMS suggested that reentry into single-use parenteral medication vials (i.e., to administer medication to more than one patient), when performed on a limited basis and under strict conditions in hemodialysis settings, likely would result in low risk for bacterial infection.8 However, the 2002 communication did not address risks for bloodborne viral infections (e.g., HCV and hepatitis B virus infection). This report is intended to clarify and restate CDC's recommendation on parenteral medication to include bloodborne viral infections. The recommendations in this report supersede the 2002 CDC communication to CMS.

To prevent transmission of both bacteria and bloodborne viruses in hemodialysis settings, CDC recommends that all single-use injectable medications and solutions be dedicated for use on a single patient and be entered one time only. Medications packaged as multidose should be assigned to a single patient whenever possible. All parenteral medications should be prepared in a clean area separate from potentially contaminated items and surfaces. In hemodialysis settings where environmental surfaces and medical supplies are subjected to frequent blood contamination, medication preparation should occur in a clean area removed from the patient treatment area. Proper infection control practices must be followed during the preparation and administration of injected medications.9 This is consistent with official CDC recommendations for infection control precautions in hemodialysis2 and other health-care settings.9

Health departments and other public health partners should be aware of the new CMS conditions for ESRD facilities. All dialysis providers are advised to follow official CDC recommendations regarding Standard Precautions and infection control in dialysis settings.2,9 Specifically, CDC has recommended the following: “Intravenous medication vials labeled for single use, including erythropoietin, should not be punctured more than once. Once a needle has entered a vial labeled for single use, the sterility of the product can no longer be guaranteed.”2 Additional guidance on safe injection practices can be found in the Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings 2007.9

Dialysis providers also should be aware of their responsibility to report clusters of infections or other adverse events to the appropriate local or state public health authority. Failure to report illness clusters to public health authorities can result in delays in recognition of disease outbreaks10 and implementation of control measures. Additional information regarding the new CMS Conditions for Coverage for End-Stage Renal Disease Facilities is available at http://www.cms.hhs.gov/cfcsandcops/13_esrd.asp.

REFERENCES

US Department of Health and Human Services. Centers for Medicare and Medicaid Services.  Medicare and Medicaid programs; conditions for coverage for end-stage renal disease facilities. 42 CFR Parts 405, 410, 413, 414, 488, and 494. Available at http://www.cms.hhs.gov/cfcsandcops/downloads/esrdfinalrule0415.pdf
CDC.  Recommendations for preventing transmission of infections among chronic hemodialysis patients.  MMWR. 2001;50:(No. RR-5)  1-43
Thompson N, Bialek S. Hepatitis C virus transmission in the hemodialysis setting: importance of infection control practices and aseptic technique [Abstract]. In: programs and abstracts of the National Kidney Foundation Spring Meeting; April 3, 2008; Grapevine, TX
CDC.  Acute hepatitis C virus infections attributed to unsafe injection practices at an endoscopy clinic—Nevada, 2007.  MMWR Morb Mortal Wkly Rep. 2008;57(19):513-517
PubMed
Williams IT, Perz JF, Bell BP. Viral hepatitis transmission in ambulatory health care settings.  Clin Infect Dis. 2004;38(11):1592-1598
PubMed   |  Link to Article
Alter MJ. Healthcare should not be a vehicle for transmission of hepatitis C virus.  J Hepatol. 2008;48(1):2-4
PubMed   |  Link to Article
Grohskopf LA, Roth VR, Feikin DR,  et al.  Serratia liquefaciens bloodstream infections from contamination of epoetin alfa at a hemodialysis center.  N Engl J Med. 2001;344(20):1491-1497
PubMed   |  Link to Article
Department of Health and Human Services. Centers for Medicare and Medicaid Services.  CDC revised recommendations for single-use intravenous medication vials in end-stage renal disease (ESRD) facilities, 2002. Available at http://www.cms.hhs.gov/surveycertificationgeninfo/downloads/scletter02-43.pdf
Siegel JD, Rhinehart E, Jackson M, Chiarello L.Healthcare Infection Control Practices Advisory Committee.  Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings 2007. Atlanta, GA: US Department of Health and Human Services, CDC; 2007. Available at http://www.cdc.gov/ncidod/dhqp/gl_isolation.html
CDC.  Acute allergic-type reactions among patients undergoing hemodialysis—multiple states, 2007-2008.  MMWR Morb Mortal Wkly Rep. 2008;57(5):124-125
PubMed

Figures

Tables

References

US Department of Health and Human Services. Centers for Medicare and Medicaid Services.  Medicare and Medicaid programs; conditions for coverage for end-stage renal disease facilities. 42 CFR Parts 405, 410, 413, 414, 488, and 494. Available at http://www.cms.hhs.gov/cfcsandcops/downloads/esrdfinalrule0415.pdf
CDC.  Recommendations for preventing transmission of infections among chronic hemodialysis patients.  MMWR. 2001;50:(No. RR-5)  1-43
Thompson N, Bialek S. Hepatitis C virus transmission in the hemodialysis setting: importance of infection control practices and aseptic technique [Abstract]. In: programs and abstracts of the National Kidney Foundation Spring Meeting; April 3, 2008; Grapevine, TX
CDC.  Acute hepatitis C virus infections attributed to unsafe injection practices at an endoscopy clinic—Nevada, 2007.  MMWR Morb Mortal Wkly Rep. 2008;57(19):513-517
PubMed
Williams IT, Perz JF, Bell BP. Viral hepatitis transmission in ambulatory health care settings.  Clin Infect Dis. 2004;38(11):1592-1598
PubMed   |  Link to Article
Alter MJ. Healthcare should not be a vehicle for transmission of hepatitis C virus.  J Hepatol. 2008;48(1):2-4
PubMed   |  Link to Article
Grohskopf LA, Roth VR, Feikin DR,  et al.  Serratia liquefaciens bloodstream infections from contamination of epoetin alfa at a hemodialysis center.  N Engl J Med. 2001;344(20):1491-1497
PubMed   |  Link to Article
Department of Health and Human Services. Centers for Medicare and Medicaid Services.  CDC revised recommendations for single-use intravenous medication vials in end-stage renal disease (ESRD) facilities, 2002. Available at http://www.cms.hhs.gov/surveycertificationgeninfo/downloads/scletter02-43.pdf
Siegel JD, Rhinehart E, Jackson M, Chiarello L.Healthcare Infection Control Practices Advisory Committee.  Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings 2007. Atlanta, GA: US Department of Health and Human Services, CDC; 2007. Available at http://www.cdc.gov/ncidod/dhqp/gl_isolation.html
CDC.  Acute allergic-type reactions among patients undergoing hemodialysis—multiple states, 2007-2008.  MMWR Morb Mortal Wkly Rep. 2008;57(5):124-125
PubMed
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
JAMAevidence.com

Care at the Close of Life EDUCATION GUIDES
Practical Considerations in Dialysis Withdrawal


Hemodialysis